Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Oct 5;1(6):e183377.
doi: 10.1001/jamanetworkopen.2018.3377.

Effect of 2 Clinical Decision Support Strategies on Chronic Kidney Disease Outcomes in Primary Care: A Cluster Randomized Trial

Jennifer K Carroll  1   2 , Gerald Pulver  1 , L Miriam Dickinson  1 , Wilson D Pace  3 , Joseph A Vassalotti  4   5 , Kim S Kimminau  2   6 , Brian K Manning  2 , Elizabeth W Staton  1 , Chester H Fox  7
Affiliations
Randomized Controlled Trial

Effect of 2 Clinical Decision Support Strategies on Chronic Kidney Disease Outcomes in Primary Care: A Cluster Randomized Trial

Jennifer K Carroll et al. JAMA Netw Open. .

Abstract

Importance: Information is needed about optimal strategies to improve evidence-based treatment of chronic kidney disease (CKD) in primary care.

Objective: To determine whether a multimodal intervention delays annualized loss of estimated glomerular filtration rate (eGFR) in stages 3 and 4 CKD.

Design, setting, and participants: This pragmatic cluster randomized clinical trial enrolled 42 primary care practices located in nonhospital settings with electronic health record systems. Practices were recruited through the American Academy of Family Physicians National Research Network. The study was conducted January 2013 through January 2016.

Interventions: Practices were randomized at the organization level to either the clinical decision support (CDS) plus practice facilitation (PF) group (n = 25) or CDS group (n = 17) using covariate constrained randomization. Both groups received point-of-care CDS to prompt screening, diagnosis, and treatment of CKD; the intervention group also received PF based on the 9-point TRANSLATE model (target, use point-of-care reminder systems, get administrative buy-in, network information systems using registries, site coordination, local physician champion, audit and feedback, team approach, and education).

Main outcomes and measures: The primary outcome measure was eGFR over time. Secondary outcome measures were systolic blood pressure over time, change in hemoglobin A1c (HbA1c) over time, avoidance of nonsteroidal anti-inflammatory medications, use of angiotensin converting enzyme inhibitor or angiotensin-renin blocker medication, early recognition and diagnosis of CKD, blood pressure control, and smoking cessation.

Results: In this cluster randomized trial of 30 primary care practices comprising 6699 patients, there were 1685 patients in the control group (10 practices) and 5014 patients in the intervention group (20 practices). The final sample of practices differed from the original set of randomized practices owing to dropout. Patients in the practices were similar at baseline for age (mean [SD], 71.3 [9.6] years), sex (2716 male [40.5%]), and eGFR. There was a significant difference in eGFR slopes for patients in the intervention vs control group practices. The mean (SE) annualized loss of eGFR was 0.95 (0.19) in the control group in propensity-adjusted longitudinal analyses and 0.01 (0.12) in the intervention group (mean [SE] difference in slopes, 0.93 [0.23]; P < .001). Among patients with HbA1c measures, slopes differed significantly for patients in intervention vs control practices, with a mean (SE) annualized increase of 0.14 (0.03) in HbA1c for patients in control practices and a mean (SE) decline of 0.009 (0.02) for patients in intervention practices. There was a significant difference in HbA1c slopes for patients in the intervention compared with control group practices (control vs intervention, -0.14; P < .001), but no difference in the other secondary outcomes.

Conclusions and relevance: A multimodal intervention in primary care, based on the TRANSLATE model, slowed annualized loss of eGFR. This study had several important strengths, weaknesses, and lessons learned regarding the implementation of pragmatic interventions in primary care to improve CKD outcomes.

Trial registration: ClinicalTrials.gov Identifier: NCT01767883.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Carroll reports grants from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) during the conduct of the study. Dr Dickinson reports grants from the National Research Network during the conduct of the study. Dr Vassalotti reports grants from National Institutes of Health during the conduct of the study and personal fees from Merck and KPMG outside the submitted work. Dr Pace reports grants from the NIDDK during the conduct of the study. Ms Staton reports support from the American Academy of Family Physicians during the conduct of the study in the form of a standing contract for staff time paid to the University of Colorado Denver Department of Family Physicians. Dr Fox reports grants from the NIDDK during the conduct of the study.

Figures

Figure 1.
Figure 1.. CONSORT Diagram
Practices and patients from eligibility assessment through outcomes assessment. CDS indicates clinical decision support; eGFR, estimated glomerular filtration rate; and PF, practice facilitation.
Figure 2.
Figure 2.. Model-Based Estimates of Estimated Glomerular Filtration Rate (eGFR) Over Time
See this image and copyright information in PMC

Comment in

References

    1. Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance System—United States. Crude prevalence of CKD stages 1-4, 1999-2014. https://nccd.cdc.gov/ckd/detail.aspx?Qnum=Q9. Accessed November 2, 2017.
    1. Shahinian VB, Hedgeman E, Gillespie BW, et al. ; CDC CKD Surveillance System . Estimating prevalence of CKD stages 3-5 using health system data. Am J Kidney Dis. 2013;61(6):-. doi: 10.1053/j.ajkd.2013.01.018 - DOI - PMC - PubMed
    1. Collins AJ, Foley RN, Chavers B, et al. US Renal Data System 2013 annual data report. Am J Kidney Dis. 2014;63(1)(suppl):A7. doi: 10.1053/j.ajkd.2013.11.001 - DOI - PubMed
    1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659-663. doi: 10.1001/archinte.164.6.659 - DOI - PubMed
    1. Fox CH, Brooks A, Zayas LE, McClellan W, Murray B. Primary care physicians’ knowledge and practice patterns in the treatment of chronic kidney disease: an Upstate New York Practice-based Research Network (UNYNET) study. J Am Board Fam Med. 2006;19(1):54-61. doi: 10.3122/jabfm.19.1.54 - DOI - PubMed

Publication types

Substances

Associated data